Predictions for prophylaxis and antiretroviral therapy While it has long been suspected that HIV prevalence among educators is high, there has been no scientific study to assess this. Responding to the need for empirical evidence, the Education Labour Relations Council (ELRC) commissioned the Human Sciences Research Council-led consortium to conduct this nationwide research assessing the prevalence of HIV/AIDS, as well as issues such as the health status and attrition of our educators. The results of the research suggest that the high number of our educators living with AIDS is cause for serious concern. This report is part of a broader report and presents predictions for prophylaxis and antiretroviral therapy. The ELRC, as representative of both employers and unions, is best suited to facilitate the means to address the recommendations of this study.
Predictions for prophylaxis and antiretroviral therapy While it has long been suspected that HIV prevalence among educators is high, there has been no scientific study to assess this. Responding to the need for empirical evidence, the Education Labour Relations Council (ELRC) commissioned the Human Sciences Research Council-led consortium to conduct this nationwide research assessing the prevalence of HIV/AIDS, as well as issues such as the health status and attrition of our educators. The results of the research suggest that the high number of our educators living with AIDS is cause for serious concern. This report is part of a broader report and presents predictions for prophylaxis and antiretroviral therapy. The ELRC, as representative of both employers and unions, is best suited to facilitate the means to address the recommendations of this study.
List of tables and figures
Abbreviations
1. Background
2. Objectives and methodology
3. Results
4. Discussion
5. Conclusion and recommendations
6. References
Appendix
A Results of forensic audit conducted at CLS, January 2005
B Description of PLG CD4 methodology used
C Conclusions and recommendations
Addendum 1: PLG CD4: Extended window of testing to 5 days
Addendum 2: Supportive data from R&D, BCI, Miami, FL, USA
Addendum 3: Table of cross-platform equivalency testing
Addendum 4: Performance of laboratories participating in the WHO/QASI/NHLS CD4 REQAS
Bibliography/references